What is Modulight Bio?
Modulight Biotherapeutics is at the forefront of developing a precision neuromodulation platform that leverages optogenetics to address severe neurological disorders. The company's core mission is to deliver rapid and precise therapeutic relief for patients afflicted with conditions such as seizures, tremors, and neuropathic pain. Currently, Modulight is focusing its clinical development efforts on trigeminal neuropathic pain as its initial indication. By harnessing the therapeutic potential of light, Modulight aims to revolutionize the treatment landscape for individuals managing debilitating neurological challenges.
How much funding has Modulight Bio raised?
Modulight Bio has raised a total of $12.2M across 1 funding round:
Seed
$12.2M
Seed (2025): $12.2M with participation from LocalGlobe, Sara Capital, Secret Chord Ventures, SilverArc Capital, and Jibe Ventures
Key Investors in Modulight Bio
LocalGlobe
LocalGlobe is an investor participating in the funding round. Further details on their investment focus are not provided.
Sara Capital
Sara Capital Group is a full-service provider of real estate solutions focused on multicultural markets in the Southeastern United States. Their participation in this funding round suggests a potential diversification of their investment portfolio or a strategic interest in the biotechnology sector.
Secret Chord Ventures
Secret Chord Ventures is an Israel-based early-stage venture firm that invests in exceptional entrepreneurs aiming to create category-defining companies. Their involvement indicates a focus on supporting Modulight Bio's early-stage development and growth.
What's next for Modulight Bio?
The recent major strategic investment signifies a pivotal moment for Modulight Bio, likely enabling the company to accelerate its clinical trial programs and further refine its optogenetic neuromodulation technology. This substantial backing suggests confidence from investors in Modulight's approach to treating neurological disorders. The company is expected to focus on advancing its trigeminal neuropathic pain indication towards regulatory approval, while potentially exploring other neurological conditions where its platform can offer a significant therapeutic advantage. Continued investment will be crucial for scaling operations, expanding the research and development team, and navigating the complex regulatory pathways inherent in the biotechnology sector.
See full Modulight Bio company page
